

Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B

New England Journal of Medicine

384, 1899-1909

DOI: [10.1056/nejmoa2103055](https://doi.org/10.1056/nejmoa2103055)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses. <i>Emerging Microbes and Infections</i> , 2021, 10, 1931-1946.	3.0	11
2	Efficacy and Safety of the CVnCoV SARS-CoV-2 mRNA Vaccine Candidate: Results from Herald, a Phase 2b/3, Randomised, Observer-Blinded, Placebo-Controlled Clinical Trial in Ten Countries in Europe and Latin America. <i>SSRN Electronic Journal</i> , 0, , .	0.4	7
3	Concern About the Adverse Effects of Thrombocytopenia and Thrombosis After Adenovirus-Vectored COVID-19 Vaccination. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962110401.	0.7	6
4	Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative caseâ€“control real-world study. <i>Emerging Microbes and Infections</i> , 2021, 10, 1751-1759.	3.0	206
5	Increased Risk of Hospitalisation and Intensive Care Admission Associated With Infection With SARS-CoV-2 Variants B.1.1.7 and B.1.351 in Norway, December 2020 â€“ May 2021. <i>SSRN Electronic Journal</i> , 0, , .	0.4	4
6	The challenge of emerging SARS-CoV-2 mutants to vaccine development. <i>Journal of Genetics and Genomics</i> , 2021, 48, 102-106.	1.7	19
8	Will SARS-CoV-2 variants of concern affect the promise of vaccines?. <i>Nature Reviews Immunology</i> , 2021, 21, 340-341.	10.6	162
9	Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection. <i>Nature Reviews Immunology</i> , 2021, 21, 395-404.	10.6	223
17	The need for global access to biomedical innovations during pandemics. <i>Nature Biotechnology</i> , 2021, 39, 664-666.	9.4	13
18	Anti-SARS-CoV-2 Antibodies Testing in Recipients of COVID-19 Vaccination: Why, When, and How?. <i>Diagnostics</i> , 2021, 11, 941.	1.3	45
19	Interplay between Emerging SARS-CoV-2 Variants and Pandemic Control. <i>New England Journal of Medicine</i> , 2021, 384, 1952-1954.	13.9	19
21	SARS-CoV-2 escaped natural immunity, raising questions about vaccines and therapies. <i>Nature Medicine</i> , 2021, 27, 759-761.	15.2	65
22	Pfizer COVID vaccine protects against worrying coronavirus variants. <i>Nature</i> , 2021, 593, 325-326.	13.7	14
25	The Immunopathobiology of SARS-CoV-2 Infection. <i>FEMS Microbiology Reviews</i> , 2021, 45, .	3.9	9
26	Preparing for COVID-19 Vaccination: Guidances for Healthcare Personnel. <i>Korean Journal of Healthcare-Associated Infection Control and Prevention</i> , 2021, 26, 3-15.	0.1	1
28	SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise. <i>Microorganisms</i> , 2021, 9, 1389.	1.6	4
29	The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3546-3567.	2.0	152
30	SARS-CoV-2 variants, spike mutations and immune escape. <i>Nature Reviews Microbiology</i> , 2021, 19, 409-424.	13.6	2,650

#	ARTICLE	IF	CITATIONS
32	Models and Mechanisms for COVID-19 Research. <i>DMM Disease Models and Mechanisms</i> , 2021, 14, .	1.2	1
34	Coronavirus disease 2019 vaccination in transplant recipients. <i>Current Opinion in Infectious Diseases</i> , 2021, 34, 275-287.	1.3	15
35	Meta-Analysis and Structural Dynamics of the Emergence of Genetic Variants of SARS-CoV-2. <i>Frontiers in Microbiology</i> , 2021, 12, 676314.	1.5	17
38	SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies. <i>Viruses</i> , 2021, 13, 1211.	1.5	35
40	Six months of COVID vaccines: what 1.7 billion doses have taught scientists. <i>Nature</i> , 2021, 594, 164-167.	13.7	61
42	Comprehensive Understanding and Field Application of COVID-19 Vaccine. <i>Korean Journal of Medicine</i> , 2021, 96, 155-159.	0.1	8
43	Willingness to Receive COVID-19 Vaccination Among People Living With HIV and AIDS in China: Nationwide Cross-sectional Online Survey. <i>JMIR Public Health and Surveillance</i> , 2021, 7, e31125.	1.2	33
44	SARS-CoV-2 Antiviral Therapy. <i>Clinical Microbiology Reviews</i> , 2021, 34, e0010921.	5.7	64
46	Recent updates on immunological, pharmacological, and alternative approaches to combat COVID-19. <i>Inflammopharmacology</i> , 2021, 29, 1331-1346.	1.9	7
47	A Comprehensive Review of COVID-19 Virology, Vaccines, Variants, and Therapeutics. <i>Current Medical Science</i> , 2021, 41, 1037-1051.	0.7	136
50	The impact of spike mutated variants of SARS-CoV2 [Alpha, Beta, Gamma, Delta, and Lambda] on the efficacy of subunit recombinant vaccines. <i>Brazilian Journal of Infectious Diseases</i> , 2021, 25, 101606.	0.3	94
51	Using Adjuvants to Drive T Cell Responses for Next-Generation Infectious Disease Vaccines. <i>Vaccines</i> , 2021, 9, 820.	2.1	18
52	Analysis of Delayed Vaccination Regimens: A Mathematical Modeling Approach. <i>Epidemiologia</i> , 2021, 2, 271-293.	1.1	13
54	The success of SARS-CoV-2 vaccines and challenges ahead. <i>Cell Host and Microbe</i> , 2021, 29, 1111-1123.	5.1	67
56	COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies. <i>Biomolecules</i> , 2021, 11, 993.	1.8	136
57	COVID-19 Pathogenesis: From Molecular Pathway to Vaccine Administration. <i>Biomedicines</i> , 2021, 9, 903.	1.4	5
58	Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants Induced by Natural Infection or Vaccination: A Systematic Review and Pooled Analysis. <i>Clinical Infectious Diseases</i> , 2022, 74, 734-742.	2.9	88
59	SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2. <i>Cell</i> , 2021, 184, 3936-3948.e10.	13.5	241

#	ARTICLE	IF	CITATIONS
61	The Genomic Landscape of Severe Acute Respiratory Syndrome Coronavirus 2. <i>Advances in Molecular Pathology</i> , 2021, 4, 231-235.	0.2	4
63	Vaccine Development against COVID-19: Study from Pre-Clinical Phases to Clinical Trials and Global Use. <i>Vaccines</i> , 2021, 9, 836.	2.1	15
64	Grand Challenges in Molecular Medicine for Disease Prevention and Treatment Through Cyclical Innovation. <i>Frontiers in Molecular Medicine</i> , 2021, 1, .	0.6	2
65	Rapid evolution of the COVID-19 pandemic calls for a unified public health response. <i>BioScience Trends</i> , 2021, 15, 196-200.	1.1	5
66	Putative Role of Vitamin D for COVID-19 Vaccination. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8988.	1.8	32
67	Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. <i>New England Journal of Medicine</i> , 2021, 385, 585-594.	13.9	2,411
68	SARS-CoV-2 Vaccines: Where Are We Now?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3535-3543.	2.0	36
70	Accelerated COVID-19 vaccine development: milestones, lessons, and prospects. <i>Immunity</i> , 2021, 54, 1636-1651.	6.6	165
71	Factors Affecting the Antibody Immunogenicity of Vaccines against SARS-CoV-2: A Focused Review. <i>Vaccines</i> , 2021, 9, 869.	2.1	17
74	Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. <i>Cell</i> , 2021, 184, 4220-4236.e13.	13.5	630
75	Clinical and Virological Features of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern: A Retrospective Cohort Study Comparing B.1.1.7 (Alpha), B.1.351 (Beta), and B.1.617.2 (Delta). <i>Clinical Infectious Diseases</i> , 2022, 75, e1128-e1136.	2.9	323
76	Jumping a Moving Train: SARS-CoV-2 Evolution in Real Time. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, 10, S96-S105.	0.6	9
77	The protective immunity induced by SARS-CoV-2 infection and vaccination: a critical appraisal. <i>Exploration of Immunology</i> , 2021, , 199-225.	1.7	5
78	mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates. <i>Nature Immunology</i> , 2021, 22, 1306-1315.	7.0	57
79	Emergency use of COVID-19 vaccines recommended by the World Health Organization (WHO) as of June 2021. <i>Drug Discoveries and Therapeutics</i> , 2021, 15, 222-224.	0.6	16
82	Effect of SARS-CoV-2 Mutations on the Efficacy of Antibody Therapy and Response to Vaccines. <i>Vaccines</i> , 2021, 9, 914.	2.1	20
83	Potential Immunomodulatory Properties of Biologically Active Components of Spices Against SARS-CoV-2 and Pan β -Coronaviruses. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 729622.	1.8	11
84	Novel SARS-CoV-2 variants: the pandemics within the pandemic. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1109-1117.	2.8	290

#	ARTICLE	IF	CITATIONS
85	Anti-COVID-19 Vaccination in Patients with Autoimmune-Autoinflammatory Disorders and Primary/Secondary Immunodeficiencies: The Position of the Task Force on Behalf of the Italian Immunological Societies. <i>Biomedicines</i> , 2021, 9, 1163.	1.4	18
86	Genomic surveillance to combat COVID-19: challenges and opportunities. <i>Lancet Microbe</i> , The, 2021, 2, e481-e484.	3.4	122
87	Exploring the immune evasion of SARS-CoV-2 variant harboring E484K by molecular dynamics simulations. <i>Briefings in Bioinformatics</i> , 2022, 23, .	3.2	19
89	Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination. <i>Cell Reports Medicine</i> , 2021, 2, 100405.	3.3	110
90	Vaccine nationalism and the dynamics and control of SARS-CoV-2. <i>Science</i> , 2021, 373, eabj7364.	6.0	80
91	COVID-19 Infection in Children, Infants and Pregnant Subjects: An Overview of Recent Insights and Therapies. <i>Microorganisms</i> , 2021, 9, 1964.	1.6	13
92	Fast and long-lasting immune response to S-trimer COVID-19 vaccine adjuvanted by PIKA. <i>Molecular Biomedicine</i> , 2021, 2, 29.	1.7	10
93	Achieving global equity for COVID-19 vaccines: Stronger international partnerships and greater advocacy and solidarity are needed. <i>PLoS Medicine</i> , 2021, 18, e1003772.	3.9	7
94	Single-dose intranasal vaccination elicits systemic and mucosal immunity against SARS-CoV-2. <i>IScience</i> , 2021, 24, 103037.	1.9	66
97	COVID-19 Vaccinations: A Comprehensive Review of Their Safety and Efficacy in Special Populations. <i>Vaccines</i> , 2021, 9, 1097.	2.1	27
98	Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. <i>New England Journal of Medicine</i> , 2021, 385, 1172-1183.	13.9	734
99	Clinical features and laboratory findings first case of B. 1.617.2 (delta) variant concern (VOC) in Iraq. <i>Annals of Medicine and Surgery</i> , 2021, 69, 102814.	0.5	7
100	The future of tumor vaccines in the postâ€œCOVIDâ€œ19 eraâ€œ”Current challenges. <i>Immunity, Inflammation and Disease</i> , 2021, 9, 1795-1797.	1.3	2
102	The emergence and ongoing convergent evolution of the SARS-CoV-2 N501Y lineages. <i>Cell</i> , 2021, 184, 5189-5200.e7.	13.5	186
103	The biological and clinical significance of emerging SARS-CoV-2 variants. <i>Nature Reviews Genetics</i> , 2021, 22, 757-773.	7.7	778
104	The Immune Response to SARS-CoV-2 and Variants of Concern. <i>Viruses</i> , 2021, 13, 1911.	1.5	18
105	Possible future waves of SARS-CoV-2 infection generated by variants of concern with a range of characteristics. <i>Nature Communications</i> , 2021, 12, 5730.	5.8	90
107	Humoral and cellular immunity and the safety of COVID-19 vaccines: a summary of data published by 21 May 2021. <i>International Immunology</i> , 2021, 33, 529-540.	1.8	28

#	ARTICLE	IF	CITATIONS
109	Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in France. <i>Lancet Regional Health - Europe</i> , The, 2021, 8, 100171.	3.0	70
110	The real-life impact of vaccination on COVID-19 mortality in Europe and Israel. <i>Public Health</i> , 2021, 198, 230-237.	1.4	70
111	SARS-CoV-2-specific T cells in infection and vaccination. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2307-2312.	4.8	131
112	Vaccines and variants: Modelling insights into emerging issues in COVID-19 epidemiology. <i>Paediatric Respiratory Reviews</i> , 2021, 39, 32-39.	1.2	18
113	Development of a model-inference system for estimating epidemiological characteristics of SARS-CoV-2 variants of concern. <i>Nature Communications</i> , 2021, 12, 5573.	5.8	36
114	Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis. <i>Nature Medicine</i> , 2021, 27, 2025-2031.	15.2	361
115	COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 690621.	1.8	60
116	Engineered SARS-CoV-2 receptor binding domain improves manufacturability in yeast and immunogenicity in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	68
118	Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial. <i>PLoS Medicine</i> , 2021, 18, e1003769.	3.9	83
119	A focused review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines. <i>International Immunopharmacology</i> , 2021, 100, 108162.	1.7	65
121	Immunology of SARS-CoV-2 infections and vaccines. <i>Advances in Immunology</i> , 2021, 151, 49-97.	1.1	12
122	Comparing Immune Responses to Inactivated Vaccines Against SARS-CoV-2 Between People Living With HIV and HIV-Negative Individuals: A Cross-Sectional Study In China. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
123	Characterization of Specific Humoral Immunity in Asymptomatic SARS-CoV-2 Infection. <i>Infectious Diseases & Immunity</i> , 2021, 1, 153-160.	0.2	0
124	Review: Development of SARS-CoV-2 immuno-enhanced COVID-19 vaccines with nano-platform. <i>Nano Research</i> , 2022, 15, 2196-2225.	5.8	8
125	HIV status alters disease severity and immune cell responses in Beta variant SARS-CoV-2 infection wave. <i>ELife</i> , 2021, 10, .	2.8	28
126	Whole Inactivated Virus and Protein-Based COVID-19 Vaccines. <i>Annual Review of Medicine</i> , 2022, 73, 55-64.	5.0	55
127	Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. <i>Clinical Microbiology and Infection</i> , 2022, 28, 202-221.	2.8	569
128	COVID-19 Risk Assessment for the Tokyo Olympic Games. <i>Frontiers in Public Health</i> , 2021, 9, 730611.	1.3	9

#	ARTICLE	IF	CITATIONS
129	Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern. <i>Nature Microbiology</i> , 2021, 6, 1433-1442.	5.9	94
130	The SARS-CoV-2 pandemic: remaining uncertainties in our understanding of the epidemiology and transmission dynamics of the virus, and challenges to be overcome. <i>Interface Focus</i> , 2021, 11, 20210008.	1.5	24
131	Update on Coronavirus 2019 Vaccine Guidelines for Transplant Recipients. <i>Transplantation Proceedings</i> , 2022, 54, 1399-1404.	0.3	16
132	Diverse vaccine platforms safeguarding against SARS-CoV-2 and its variants. <i>Expert Review of Vaccines</i> , 2022, 21, 47-67.	2.0	3
134	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil. <i>Nature Communications</i> , 2021, 12, 5861.	5.8	38
136	COVID-19 Vaccine Platforms: Challenges and Safety Contemplations. <i>Vaccines</i> , 2021, 9, 1196.	2.1	15
137	Virologic Features of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children. <i>Journal of Infectious Diseases</i> , 2021, 224, 1821-1829.	1.9	53
138	Beta RBD boost broadens antibody-mediated protection against SARS-CoV-2 variants in animal models. <i>Cell Reports Medicine</i> , 2021, 2, 100450.	3.3	17
139	Efficacy, Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 2021, 12, 714170.	2.2	145
140	Increased risk of hospitalisation and intensive care admission associated with reported cases of SARS-CoV-2 variants B.1.1.7 and B.1.351 in Norway, December 2020 – May 2021. <i>PLoS ONE</i> , 2021, 16, e0258513.	1.1	37
141	The COVID-19 pandemic: viral variants and vaccine efficacy. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2022, 59, 66-75.	2.7	61
142	National strategies for vaccination against COVID-19 in people living with HIV in Central and Eastern European region. <i>HIV Medicine</i> , 2022, 23, 546-552.	1.0	7
143	Identification of conserved SARS-CoV-2 spike epitopes that expand public cTfh clonotypes in mild COVID-19 patients. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	24
145	Specific Protein Antigen Delivery to Human Langerhans Cells in Intact Skin. <i>Frontiers in Immunology</i> , 2021, 12, 732298.	2.2	9
146	Multidisciplinary Effort and Integrative Preparedness: A Lesson for the Foreseen Multivariate COVID-19 Pandemic Flare-Up. <i>Journal of Multidisciplinary Healthcare</i> , 2021, Volume 14, 2905-2921.	1.1	2
148	A practical approach to SARS-CoV-2 testing in a pre and post-vaccination era. <i>Journal of Clinical Virology Plus</i> , 2021, 1, 100044.	0.4	2
149	Prevention and Treatment of SARS-CoV2 Infection in People Living with HIV: The Need for Specific Data. <i>Infectious Diseases and Therapy</i> , 2021, , 1.	1.8	6
150	Clinical outcomes and cost-effectiveness of COVID-19 vaccination in South Africa. <i>Nature Communications</i> , 2021, 12, 6238.	5.8	31

#	ARTICLE	IF	CITATIONS
151	Scientific rationale for developing potent RBD-based vaccines targeting COVID-19. <i>Npj Vaccines</i> , 2021, 6, 128.	2.9	102
153	COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. <i>Lancet Haematology</i> , 2021, 8, e934-e946.	2.2	46
155	Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice. <i>Vaccine</i> , 2021, 39, 7394-7400.	1.7	63
156	A review of epidemiology, clinical features and disease course, transmission dynamics, and neutralization efficacy of SARS-CoV-2 variants. <i>Egyptian Journal of Bronchology</i> , 2021, 15, .	0.3	4
157	Immunogenic and efficacious SARS-CoV-2 vaccine based on resistin-trimerized spike antigen SmT1 and SLA archaeosome adjuvant. <i>Scientific Reports</i> , 2021, 11, 21849.	1.6	26
158	SARS-CoV-2 variants and effectiveness of vaccines: a review of current evidence. <i>Epidemiology and Infection</i> , 2021, 149, 1-24.	1.0	43
159	Recombinant protein subunit SARS-CoV-2 vaccines formulated with CoVaccine HT [®] , [®] adjuvant induce broad, Th1 biased, humoral and cellular immune responses in mice. <i>Vaccine: X</i> , 2021, 9, 100126.	0.9	13
160	The way of SARS-CoV-2 vaccine development: success and challenges. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 387.	7.1	42
161	SARS-CoV-2 and HIV-1: Should HIV-1-Infected Individuals in Sub-Saharan Africa Be Considered a Priority Group for the COVID-19 Vaccines?. <i>Frontiers in Immunology</i> , 2021, 12, 797117.	2.2	4
162	Update on geographical variation and distribution of SARS-nCoV-2: A systematic review. <i>Indian Journal of Pharmacology</i> , 2021, 53, 310-316.	0.4	3
164	Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2022, 10, 167-179.	5.2	89
165	Self-reported mask-related worrying reduces relative avoidance bias toward unmasked faces in individuals with low Covid19 anxiety syndrome. <i>Cognitive Research: Principles and Implications</i> , 2021, 6, 75.	1.1	7
166	The Role of Serology Testing in the Context of Immunization Policies for COVID-19 in Latin American Countries. <i>Viruses</i> , 2021, 13, 2391.	1.5	11
167	Impact of Chronic HIV Infection on SARS-CoV-2 Infection, COVID-19 Disease and Vaccines. <i>Current HIV/AIDS Reports</i> , 2022, 19, 5-16.	1.1	9
168	Bioengineering Strategies for Developing Vaccines against Respiratory Viral Diseases. <i>Clinical Microbiology Reviews</i> , 2022, 35, e0012321.	5.7	10
169	Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges. <i>Biomedicine</i> , 2021, 9, 1740.	1.4	16
170	The Disease Severity and Clinical Outcomes of the SARS-CoV-2 Variants of Concern. <i>Frontiers in Public Health</i> , 2021, 9, 775224.	1.3	156
171	Immune Evasive Effects of SARS-CoV-2 Variants to COVID-19 Emergency Used Vaccines. <i>Frontiers in Immunology</i> , 2021, 12, 771242.	2.2	15

#	ARTICLE	IF	CITATIONS
172	Covid-19 vaccines and variants of concern: A review. <i>Reviews in Medical Virology</i> , 2022, 32, e2313.	3.9	201
173	Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial. <i>Lancet Infectious Diseases</i> , 2022, 22, 329-340.	4.6	103
174	SARS-CoV-2 Variants and Their Relevant Mutational Profiles: Update Summer 2021. <i>Microbiology Spectrum</i> , 2021, 9, e0109621.	1.2	39
175	Reduced antibody activity against SARS-CoV-2 B.1.617.2 delta virus in serum of mRNA-vaccinated individuals receiving tumor necrosis factor- α inhibitors. <i>Med</i> , 2021, 2, 1327-1341.e4.	2.2	31
177	Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review. <i>Clinical Microbiology and Infection</i> , 2022, 28, 163-177.	2.8	120
178	Vaccine versus Variants (3Vs): Are the COVID-19 Vaccines Effective against the Variants? A Systematic Review. <i>Vaccines</i> , 2021, 9, 1305.	2.1	39
180	The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants. <i>Cell Host and Microbe</i> , 2022, 30, 53-68.e12.	5.1	52
181	The impact of coronavirus disease 2019 on people with HIV. <i>Current Opinion in Infectious Diseases</i> , 2022, 35, 9-14.	1.3	3
182	Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals. <i>Scientific Reports</i> , 2021, 11, 22848.	1.6	57
183	Effectiveness of BNT162b2 mRNA COVID-19 vaccine against SARS-CoV-2 variant Beta (B.1.351) among persons identified through contact tracing in Israel: A prospective cohort study. <i>EClinicalMedicine</i> , 2021, 42, 101190.	3.2	22
184	IFP35 as a promising biomarker and therapeutic target for the syndromes induced by SARS-CoV-2 or influenza virus. <i>Cell Reports</i> , 2021, 37, 110126.	2.9	14
185	Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung. <i>Cell</i> , 2022, 185, 113-130.e15.	13.5	64
186	Immune variants of SARS-CoV-2 could be a significant challenge for developing a pan genotype-specific vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2024, 17, 5145-5147.	1.4	0
187	Current and future nanoparticle vaccines for COVID-19. <i>EBioMedicine</i> , 2021, 74, 103699.	2.7	57
188	Recent Advances on Drugs and Vaccines for COVID-19. <i>Inquiry (United States)</i> , 2021, 58, 004695802110556.	0.5	3
189	Clinical Severity of COVID-19 Patients Admitted to Hospitals in Gauteng, South Africa During the Omicron-Dominant Fourth Wave. <i>SSRN Electronic Journal</i> , 0, , .	0.4	33
190	Comprehensive literature review on COVID-19 vaccines and role of SARS-CoV-2 variants in the pandemic. , 2021, 9, 251513552110597.	1.4	15
191	Recent advances in nanotechnology-based COVID-19 vaccines and therapeutic antibodies. <i>Nanoscale</i> , 2022, 14, 1054-1074.	2.8	22

#	ARTICLE	IF	CITATIONS
192	Virus-Like Particles: Revolutionary Platforms for Developing Vaccines Against Emerging Infectious Diseases. <i>Frontiers in Microbiology</i> , 2021, 12, 790121.	1.5	76
193	Isolation and characterization of SARS-CoV-2 Beta variant from UAE travelers. <i>Journal of Infection and Public Health</i> , 2022, 15, 182-186.	1.9	22
194	Efficacy of mRNA, adenoviral vector, and perfusion protein COVID-19 vaccines. <i>Biomedicine and Pharmacotherapy</i> , 2022, 146, 112527.	2.5	34
195	Effectiveness of the Ad26.Cov2.S Vaccine in Health Care Workers in South Africa. <i>SSRN Electronic Journal</i> , 0, , .	0.4	4
196	Potential Application of Bionanoparticles to Treat Severe Acute Respiratory Syndrome Coronavirus-2 Infection. <i>Frontiers in Nanotechnology</i> , 2022, 3, .	2.4	5
197	Immunological challenges of the "new" infections: corona viruses. , 2022, , 395-450.		2
198	Novel case of takotsubo cardiomyopathy following COVID-19 vaccination. <i>BMJ Case Reports</i> , 2022, 15, e247291.	0.2	14
199	Three waves changes, new variant strains, and vaccination effect against COVID-19 pandemic. <i>International Journal of Biological Macromolecules</i> , 2022, 204, 161-168.	3.6	147
200	Innovative vaccine approaches" a Keystone Symposia report. <i>Annals of the New York Academy of Sciences</i> , 2022, 1511, 59-86.	1.8	5
202	Hacking Commensal Bacteria to Consolidate the Adaptive Mucosal Immune Response in the Gut" Lung Axis: Future Possibilities for SARS-CoV-2 Protection. <i>BioTech</i> , 2022, 11, 3.	1.3	4
203	Pan-SARS neutralizing responses after third boost vaccination in non-human primate immunogenicity model. <i>Vaccine</i> , 2022, 40, 1289-1298.	1.7	9
204	From Bench to the Clinic: The Path to Translation of Nanotechnology-Enabled mRNA SARS-CoV-2 Vaccines. <i>Nano-Micro Letters</i> , 2022, 14, 41.	14.4	26
205	Longevity of vaccine protection: Immunological mechanism, assessment methods, and improving strategy. <i>View</i> , 2022, 3, .	2.7	7
206	Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants. <i>Vaccines</i> , 2022, 10, 72.	2.1	13
207	Obatoclox inhibits SARS-CoV-2 entry by altered endosomal acidification and impaired cathepsin and furin activity in vitro. <i>Emerging Microbes and Infections</i> , 2022, 11, 483-497.	3.0	16
208	The Variation of SARS-CoV-2 and Advanced Research on Current Vaccines. <i>Frontiers in Medicine</i> , 2021, 8, 806641.	1.2	22
209	SARS-COV-2 Variants: Differences and Potential of Immune Evasion. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 781429.	1.8	154
210	Evaluating Antibody Mediated Protection against Alpha, Beta, and Delta SARS-CoV-2 Variants of Concern in K18-hACE2 Transgenic Mice. <i>Journal of Virology</i> , 2022, 96, jvi0218421.	1.5	14

#	ARTICLE	IF	CITATIONS
211	COVID-19: Impact on the HIV and Tuberculosis Response, Service Delivery, and Research in South Africa. <i>Current HIV/AIDS Reports</i> , 2022, 19, 46-53.	1.1	26
213	A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2. <i>Cell Reports</i> , 2022, 38, 110256.	2.9	19
214	Frequency of Adverse Events in the Placebo Arms of COVID-19 Vaccine Trials. <i>JAMA Network Open</i> , 2022, 5, e2143955.	2.8	99
215	Booster vaccination strategy: Necessity, immunization objectives, immunization strategy, and safety. <i>Journal of Medical Virology</i> , 2022, 94, 2369-2375.	2.5	24
216	Vaccines to prevent COVID-19: A living systematic review with Trial Sequential Analysis and network meta-analysis of randomized clinical trials. <i>PLoS ONE</i> , 2022, 17, e0260733.	1.1	60
218	Analisis Efikasi dan Efektivitas Vaksin COVID-19 terhadap Varian SARS-CoV-2: Sebuah Tinjauan Literatur. <i>Jurnal Kedokteran Meditek</i> , 2022, 28, 107-119.	0.1	0
219	Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	55
220	HIV and SARS-CoV-2 Co-infection: Epidemiological, Clinical Features, and Future Implications for Clinical Care and Public Health for People Living with HIV (PLWH) and HIV Most-at-Risk Groups. <i>Current HIV/AIDS Reports</i> , 2022, 19, 17-25.	1.1	8
221	SARS-CoV-2 E484K Mutation Narrative Review: Epidemiology, Immune Escape, Clinical Implications, and Future Considerations. <i>Infection and Drug Resistance</i> , 2022, Volume 15, 373-385.	1.1	24
222	Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus. <i>European Heart Journal</i> , 2022, 43, 1157-1172.	1.0	297
223	Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2. <i>Cell</i> , 2022, 185, 896-915.e19.	13.5	189
224	Mitigation strategies to safely conduct HIV treatment research in the context of COVID-19. <i>Journal of the International AIDS Society</i> , 2022, 25, e25882.	1.2	2
225	A review of the safety and efficacy of current COVID-19 vaccines. <i>Frontiers of Medicine</i> , 2022, 16, 39-55.	1.5	19
226	Escape from recognition of SARS-CoV-2 variant spike epitopes but overall preservation of T cell immunity. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	77
227	The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-20.	1.4	163
228	Peculiarities of the T Cell Immune Response in COVID-19. <i>Vaccines</i> , 2022, 10, 242.	2.1	24
229	Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial. <i>Nature Medicine</i> , 2022, 28, 823-830.	15.2	26
230	Development of Receptor Binding Domain (RBD)-Conjugated Nanoparticle Vaccines with Broad Neutralization against SARS-CoV-2 Delta and Other Variants. <i>Advanced Science</i> , 2022, 9, e2105378.	5.6	12

#	ARTICLE	IF	CITATIONS
231	A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations. <i>Frontiers in Immunology</i> , 2022, 13, 801522.	2.2	73
232	Epidemiology and genetic diversity of SARS-CoV-2 lineages circulating in Africa. <i>IScience</i> , 2022, 25, 103880.	1.9	6
233	Elicitation of potent SARS-CoV-2 neutralizing antibody responses through immunization with a versatile adenovirus-inspired multimerization platform. <i>Molecular Therapy</i> , 2022, 30, 1913-1925.	3.7	21
234	SARS-CoV-2â€“Specific Vaccine Candidates; the Contribution of Structural Vaccinology. <i>Vaccines</i> , 2022, 10, 236.	2.1	14
235	Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico. <i>New England Journal of Medicine</i> , 2022, 386, 531-543.	13.9	274
236	Effectiveness of 3 COVID-19 Vaccines in Preventing SARS-CoV-2 Infections, Januaryâ€“May 2021, Aragon, Spain. <i>Emerging Infectious Diseases</i> , 2022, 28, 591-598.	2.0	7
237	Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspective. <i>Nature Reviews Cardiology</i> , 2022, 19, 314-331.	6.1	46
238	HIV and SARS-CoV-2 Co-infection: Epidemiological, Clinical Features, and Future Implications for Clinical Care and Public Health for People Living with HIV (PLWH) and HIV Most-at-Risk Groups. <i>Current HIV/AIDS Reports</i> , 2021, 18, 518-526.	1.1	10
239	COVID-19: comprehensive review on mutations and current vaccines. <i>Archives of Microbiology</i> , 2022, 204, 8.	1.0	26
240	A third SARS-CoV-2 spike vaccination improves neutralization of variants-of-concern. <i>Npj Vaccines</i> , 2021, 6, 146.	2.9	14
241	SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact. <i>Nature Reviews Immunology</i> , 2022, 22, 57-65.	10.6	217
244	Live attenuated virus vaccine protects against SARS-CoV-2 variants of concern B.1.1.7 (Alpha) and B.1.351 (Beta). <i>Science Advances</i> , 2021, 7, eabk0172.	4.7	32
245	Covid-19: Whatever happened to the Novavax vaccine?. <i>BMJ</i> , The, 2021, 375, n2965.	3.0	4
246	SARS-CoV-2: Emergence of New Variants and Effectiveness of Vaccines. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 777212.	1.8	29
247	Vaccine efficacy in mutant SARS-CoV-2 variants. , 2021, 4, 1-12.		4
248	Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains. <i>Science Translational Medicine</i> , 2021, , eabm3302.	5.8	13
249	Immunogenic Dynamics and SARS-CoV-2 Variants Neutralization of the Heterologous ChAdOx1-S/BNT162b2 Vaccination: Secondary Analysis of the CombiVacS Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
250	Efficacy and Effectiveness of SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis. <i>Vaccines</i> , 2022, 10, 350.	2.1	44

#	ARTICLE	IF	CITATIONS
251	The COVID-19 vaccine: Attitudes and vaccination in patients with autoimmune inflammatory rheumatic diseases. <i>Rheumatology & Autoimmunity</i> , 2022, 2, 82-91.	0.3	11
252	Durability and expansion of neutralizing antibody breadth following Ad26.COV2.S vaccination of mice. <i>Npj Vaccines</i> , 2022, 7, 23.	2.9	6
253	mRNA vaccine-induced antibodies more effective than natural immunity in neutralizing SARS-CoV-2 and its high affinity variants. <i>Scientific Reports</i> , 2022, 12, 2628.	1.6	34
254	COVID-19: vaccines, efficacy and effects on variants. <i>Current Opinion in Pulmonary Medicine</i> , 2022, 28, 180-191.	1.2	24
255	Developing an Effective Peptide-Based Vaccine for COVID-19: Preliminary Studies in Mice Models. <i>Viruses</i> , 2022, 14, 449.	1.5	5
257	Mesenchymal stem cell-based treatments for COVID-19: status and future perspectives for clinical applications. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 142.	2.4	24
259	Assessing the reporting quality of randomized controlled trials on COVID-19 vaccines: a systematic review. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-8.	1.4	1
261	Molecular variants of SARS-CoV-2: antigenic properties and current vaccine efficacy. <i>Medical Microbiology and Immunology</i> , 2022, 211, 79-103.	2.6	9
262	Protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization against SARS-CoV-2 variants of concern in non-human primates. <i>Nature Communications</i> , 2022, 13, 1699.	5.8	34
263	COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 385-401.	12.5	135
264	Beyond vaccination: messaging from religious leaders can help increase adherence to COVID-19 mitigation guidelines following vaccination. A research note. <i>Social Science Journal</i> , 0, , 1-10.	0.9	8
265	SARS-CoV-2 receptor binding domain displayed on HBsAg virus-like particles elicits protective immunity in macaques. <i>Science Advances</i> , 2022, 8, eabl6015.	4.7	27
266	A systematic review on mucocutaneous presentations after COVID-19 vaccination and expert recommendations about vaccination of important immune-mediated dermatologic disorders. <i>Dermatologic Therapy</i> , 2022, 35, e15461.	0.8	31
267	A Recombinant Subunit Vaccine Induces a Potent, Broadly Neutralizing, and Durable Antibody Response in Macaques against the SARS-CoV-2 P.1 (Gamma) Variant. <i>ACS Infectious Diseases</i> , 2022, 8, 825-840.	1.8	3
269	The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines. <i>MBio</i> , 2022, 13, e0297921.	1.8	117
270	Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study. <i>Lancet, The</i> , 2022, 399, 1141-1153.	6.3	51
271	Detection, prevention and treatment of COVID-19 and opportunities for nanobiotechnology. <i>View</i> , 2022, 3, .	2.7	8
272	Recent highlights on Omicron as a new SARS-COVID-19 variant: evolution, genetic mutation, and future perspectives. <i>Journal of Drug Targeting</i> , 2022, , 1-11.	2.1	5

#	ARTICLE	IF	CITATIONS
273	COVID-19 and Seasonal Influenza Vaccination: Cross-Protection, Co-Administration, Combination Vaccines, and Hesitancy. <i>Pharmaceuticals</i> , 2022, 15, 322.	1.7	29
274	A SARS-CoV-2 Wuhan spike virosome vaccine induces superior neutralization breadth compared to one using the Beta spike. <i>Scientific Reports</i> , 2022, 12, 3884.	1.6	11
276	Current challenges in different approaches to control COVID-19: a comprehensive review. <i>Bulletin of the National Research Centre</i> , 2022, 46, 47.	0.7	4
277	Headache onset after vaccination against SARS-CoV-2: a systematic literature review and meta-analysis. <i>Journal of Headache and Pain</i> , 2022, 23, 41.	2.5	43
278	COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants. <i>Bulletin of the National Research Centre</i> , 2022, 46, 96.	0.7	25
281	Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primates. <i>Vaccine</i> , 2022, 40, 2960-2969.	1.7	5
282	Reporting and data sharing level for COVID-19 vaccine trials: A cross-sectional study. <i>EBioMedicine</i> , 2022, 78, 103962.	2.7	8
283	On the role of data, statistics and decisions in a pandemic. <i>AStA Advances in Statistical Analysis</i> , 2022, 106, 349-382.	0.4	14
284	PAKISTANâ€™S PERSPECTIVE ON COVID-19 VACCINES. <i>Gomal Journal of Medical Sciences</i> , 2021, 19, 111-116.	0.1	0
285	Safety and efficacy of the Novavax vaccineâ€™a narrative review. <i>Aging Pathobiology and Therapeutics</i> , 2021, 3, 102-106.	0.3	0
286	CTN 328: immunogenicity outcomes in people living with HIV in Canada following vaccination for COVID-19 (HIV-COV): protocol for an observational cohort study. <i>BMJ Open</i> , 2021, 11, e054208.	0.8	7
287	Molecular and Clinical Aspects of COVID-19 Vaccines and Other Therapeutic Interventions Apropos Emerging Variants of Concern. <i>Frontiers in Pharmacology</i> , 2021, 12, 778219.	1.6	0
289	Model-Based Planning and Delivery of Mass Vaccination Campaigns against Infectious Disease: Application to the COVID-19 Pandemic in the UK. <i>Vaccines</i> , 2021, 9, 1460.	2.1	8
290	Vaccination with SARS-CoV-2 variants of concern protects mice from challenge with wild-type virus. <i>PLoS Biology</i> , 2021, 19, e3001384.	2.6	15
291	Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Ad26.CoV2.S Vaccination in People Living With Human Immunodeficiency Virus (HIV). <i>Clinical Infectious Diseases</i> , 2022, 75, e857-e864.	2.9	30
292	A Capsid Virus-Like Particle-Based SARS-CoV-2 Vaccine Induces High Levels of Antibodies and Protects Rhesus Macaques. <i>Frontiers in Immunology</i> , 2022, 13, 857440.	2.2	15
293	Research progress on vaccine efficacy against SARS-CoV-2 variants of concern. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-12.	1.4	10
294	Impact of SARS-CoV-2 Gamma lineage introduction and COVID-19 vaccination on the epidemiological landscape of a Brazilian city. <i>Communications Medicine</i> , 2022, 2, .	1.9	32

#	ARTICLE	IF	CITATIONS
295	Development of antibody resistance in emerging mutant strains of SARS CoVâ€2: Impediment for COVIDâ€19 vaccines. <i>Reviews in Medical Virology</i> , 2022, 32, e2346.	3.9	16
296	A Systematic Review of Coronavirus Disease 2019 Vaccine Efficacy and Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Disease. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	62
297	Annotating Spike Protein Polymorphic Amino Acids of Variants of SARS-CoV-2, Including Omicron. <i>Biochemistry Research International</i> , 2022, 2022, 1-7.	1.5	3
299	New Normal for Lung Cancer Clinical Trials Under Coronavirus Disease 2019. <i>Journal of Thoracic Oncology</i> , 2022, 17, 588-591.	0.5	1
300	COVID-19 GPH: tracking the contribution of genomics and precision health to the COVID-19 pandemic response. <i>BMC Infectious Diseases</i> , 2022, 22, 402.	1.3	1
301	A Modified Fibronectin Type III Domain-Conjugated, Long-Acting Pan-Coronavirus Fusion Inhibitor with Extended Half-Life. <i>Viruses</i> , 2022, 14, 655.	1.5	8
303	Escape from recognition of SARS-CoV-2 Beta variant spike epitopes but overall preservation of T cell immunity.. <i>Science Translational Medicine</i> , 2021, , eabj6824.	5.8	11
304	Broadly neutralizing antibodies against SARS-CoV-2 variants. , 2022, 1, 20220005.		3
305	Covid-19: virology, variants, and vaccines. , 2022, 1, e000040.		24
306	The E484K Substitution in a SARS-CoV-2 Spike Protein Subunit Vaccine Resulted in Limited Cross-Reactive Neutralizing Antibody Responses in Mice. <i>Viruses</i> , 2022, 14, 854.	1.5	5
307	A Bivalent COVID-19 Vaccine Based on Alpha and Beta Variants Elicits Potent and Broad Immune Responses in Mice against SARS-CoV-2 Variants. <i>Vaccines</i> , 2022, 10, 702.	2.1	18
308	Status of Humoral and Cellular Immune Responses within 12 Months following CoronaVac Vaccination against COVID-19. <i>MBio</i> , 2022, 13, e0018122.	1.8	20
309	Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trial. <i>Vaccine</i> , 2022, 40, 3380-3388.	1.7	13
310	Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2. <i>Cell</i> , 2022, 185, 2265-2278.e14.	13.5	77
311	Recent developments in SARSâ€CoVâ€2 vaccines: A systematic review of the current studies. <i>Reviews in Medical Virology</i> , 2023, 33, e2359.	3.9	17
312	Effectiveness of COVID-19 vaccination among people living with HIV during a COVID-19 outbreak. <i>Journal of Microbiology, Immunology and Infection</i> , 2022, 55, 535-539.	1.5	13
313	Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates. <i>PLoS Biology</i> , 2022, 20, e3001609.	2.6	14
314	COVID-19 vaccines in pregnancy. <i>Trends in Molecular Medicine</i> , 2022, 28, 662-680.	3.5	16

#	ARTICLE	IF	CITATIONS
315	COVID-19 vaccine development: milestones, lessons and prospects. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 146.	7.1	153
316	nSARS-CoV-2 and COVID-19 Pandemic: From Emergence to Vaccination. <i>Dr Sulaiman Al Habib Medical Journal</i> , 0, , 1.	0.3	0
317	Advances in the delivery of COVID-19 vaccines. , 0, 2, 5.		0
318	Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial. <i>Lancet HIV</i> , the, 2022, 9, e309-e322.	2.1	38
319	Development of functionally relevant potency assays for monovalent and multivalent vaccines delivered by evolving technologies. <i>Npj Vaccines</i> , 2022, 7, 50.	2.9	14
321	Quadrivalent mosaic HexaPro-bearing nanoparticle vaccine protects against infection of SARS-CoV-2 variants. <i>Nature Communications</i> , 2022, 13, 2674.	5.8	26
322	SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T _H 1 cell responses more efficiently than other variants in mild COVID-19 convalescents. <i>Cell Reports Medicine</i> , 2022, 3, 100651.	3.3	24
323	COVID-19 Vaccine Breakthrough Infections and Associated Factors in Kwekwe City, Zimbabwe, 2021. <i>Open Journal of Epidemiology</i> , 2022, 12, 170-184.	0.2	0
324	A live attenuated virus-based intranasal COVID-19 vaccine provides rapid, prolonged, and broad protection against SARS-CoV-2. <i>Science Bulletin</i> , 2022, 67, 1372-1387.	4.3	54
325	Benefit-risk evaluation of COVID-19 vaccination in special population groups of interest. <i>Vaccine</i> , 2022, 40, 4348-4360.	1.7	5
326	COH04S1 and beta sequence-modified vaccine protect hamsters from SARS-CoV-2 variants. <i>IScience</i> , 2022, 25, 104457.	1.9	8
328	Comprehensive narrative review of real-world COVID-19 vaccines: viewpoints and opportunities. <i>Medical Review</i> , 2022, 2, 169-196.	0.3	5
329	SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies. <i>International Reviews of Immunology</i> , 2023, 42, 393-414.	1.5	26
330	Real-World Effectiveness of Global COVID-19 Vaccines Against SARS-CoV-2 Variants: A Systematic Review and Meta-Analysis. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	25
331	Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis. <i>BMC Medicine</i> , 2022, 20, .	2.3	149
332	Principles of SARS-CoV-2 glycosylation. <i>Current Opinion in Structural Biology</i> , 2022, 75, 102402.	2.6	27
333	Randomised trials of COVID-19 vaccines in Africa – charting the path forward. <i>South African Journal of Science</i> , 2022, 118, .	0.3	1
334	A Multivalent Vaccine Based on Ferritin Nanocage Elicits Potent Protective Immune Responses against SARS-CoV-2 Mutations. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6123.	1.8	9

#	ARTICLE	IF	CITATIONS
337	Nonhuman primate models for evaluation of SARS-CoV-2 vaccines. <i>Expert Review of Vaccines</i> , 2022, 21, 1055-1070.	2.0	1
338	Des vaccins anti-Covid sous licence pour les Japonais. <i>Revue Francophone Des Laboratoires</i> , 2022, 2022, 11.	0.0	0
339	SARS-CoV-2 vaccine challenge based on spike glycoprotein against several new variants. <i>Clinical and Experimental Vaccine Research</i> , 2022, 11, 173.	1.1	0
341	COVID-19 exit strategy during vaccine implementation: a balance between social distancing and herd immunity. <i>Archives of Virology</i> , 0, , .	0.9	1
342	Exploring the Role of Serology Testing to Strengthen Vaccination Initiatives and Policies for COVID-19 in Asia Pacific Countries and Territories: A Discussion Paper. <i>International Journal of Translational Medicine</i> , 2022, 2, 275-308.	0.1	1
343	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Africa: Current Considerations and Future Projections. <i>Clinical Infectious Diseases</i> , 2022, 75, S136-S140.	2.9	3
345	SARS-CoV-2: phenotype, genotype, and characterization of different variants. <i>Cellular and Molecular Biology Letters</i> , 2022, 27, .	2.7	12
346	COVID-19 Vaccines: Update of the vaccines in use and under development. <i>Vacunas</i> , 2022, , .	1.1	6
347	Mapping the intersection of nanotechnology and SARS-CoV-2/COVID-19: A bibliometric analysis. , 2022, 1, 103-112.		3
348	Comparison of COVID-19 Vaccines Introduced in Korea. <i>Biomedical Science Letters</i> , 2022, 28, 67-82.	0.0	1
350	Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7675.	1.8	9
351	COVID-19 vaccination efficacy in numbers including SARS-CoV-2 variants and age comparison: a meta-analysis of randomized clinical trials. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2022, 21, .	1.7	6
352	A Comprehensive Review of the Protein Subunit Vaccines Against COVID-19. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	63
354	A nanoparticle-based COVID-19 vaccine candidate elicits broad neutralizing antibodies and protects against SARS-CoV-2 infection. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2022, 44, 102584.	1.7	7
355	COVID-19 Challenge: A Quest for Effective Vaccine Strategies Against Circulating and Emerging SARS-CoV-2 Variants. <i>Current Pharmaceutical Design</i> , 2022, 28, 2901-2913.	0.9	3
357	Immunogenicity, efficacy and safety of COVID-19 vaccines: an update of data published by 31 December 2021. <i>International Immunology</i> , 2022, 34, 595-607.	1.8	19
358	Heterologous saRNA Prime, DNA Dual-Antigen Boost SARS-CoV-2 Vaccination Elicits Robust Cellular Immunogenicity and Cross-Variant Neutralizing Antibodies. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
359	Comparing reactogenicity of COVID-19 vaccines: a systematic review and meta-analysis. <i>Expert Review of Vaccines</i> , 2022, 21, 1301-1318.	2.0	12

#	ARTICLE	IF	CITATIONS
360	Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study. <i>EClinicalMedicine</i> , 2022, 50, 101529.	3.2	3
361	Unsuppressed HIV infection impairs T cell responses to SARS-CoV-2 infection and abrogates T cell cross-recognition. <i>ELife</i> , 0, 11, .	2.8	12
362	Classifying COVID-19 Variants Based on Genetic Sequences Using Deep Learning Models. <i>Springer Series in Reliability Engineering</i> , 2023, , 347-360.	0.3	3
363	Comparative characterization of antibody responses induced by Ad5-vectored spike proteins of emerging SARS-CoV-2 VOCs. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	5
364	Immune Escape Associated with RBD Omicron Mutations and SARS-CoV-2 Evolution Dynamics. <i>Viruses</i> , 2022, 14, 1603.	1.5	27
365	A bibliometric analysis of the 100 most cited articles describing SARS-CoV-2 variants. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	0
366	COVID-19 pandemic dynamics in South Africa and epidemiological characteristics of three variants of concern (Beta, Delta, and Omicron). <i>ELife</i> , 0, 11, .	2.8	36
367	Publication trends of research on COVID-19 and host immune response: A bibliometric analysis. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	6
368	A universal <scp>SARSâ€CoV DNA</scp> vaccine inducing highly crossâ€reactive neutralizing antibodies and T cells. <i>EMBO Molecular Medicine</i> , 2022, 14, .	3.3	11
369	Homologous and Heterologous Boosting of the Chadox1-S1-S COVID-19 Vaccine With the SCB-2019 Vaccine Candidate: A Randomized, Controlled, Phase 2 Study. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	9
370	Vaccines against SARS-CoV-2 variants and future pandemics. <i>Expert Review of Vaccines</i> , 2022, 21, 1363-1376.	2.0	6
371	A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
372	COVID-19 Vaccine Clinical Trials: A Birdâ€™s Eye Perspective. <i>Cureus</i> , 2022, , .	0.2	0
373	Latest in COVID-19 Vaccine 'Candidates' Race. <i>Infectious Disorders - Drug Targets</i> , 2022, 22, .	0.4	0
375	Efficacy and safety of COVIDâ€™19 vaccines: A network metaâ€analysis. <i>Journal of Evidence-Based Medicine</i> , 2022, 15, 245-262.	0.7	14
376	NVX-CoV2373 vaccination induces functional SARS-CoV-2â€™specific CD4+ and CD8+ T cell responses. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	34
377	The current status of COVID-19 vaccines. A scoping review. <i>Drug Discovery Today</i> , 2022, 27, 103336.	3.2	7
378	COVID-19 vaccine effectiveness among people living with and without HIV in South Carolina, USA: protocol of a population-based cohort study. <i>BMJ Open</i> , 2022, 12, e067095.	0.8	1

#	ARTICLE	IF	CITATIONS
379	Neutralization activity of sera/IgG preparations from fully BNT162b2 vaccinated individuals against SARS-CoV-2 Alpha, Beta, Gamma, Delta, and Kappa variants. <i>Scientific Reports</i> , 2022, 12, .	1.6	9
380	SARS-CoV-2 immunity and vaccine strategies in people with HIV. <i>Oxford Open Immunology</i> , 2022, 3, .	1.2	12
381	Selective reversed-phase high-performance liquid chromatography method for the determination of intact SARS-CoV-2 spike protein. <i>Journal of Chromatography A</i> , 2022, 1680, 463424.	1.8	2
382	Host genetic diversity and genetic variations of SARS-CoV-2 in COVID-19 pathogenesis and the effectiveness of vaccination. <i>International Immunopharmacology</i> , 2022, 111, 109128.	1.7	9
383	High-Speed railways and the spread of Covid-19. <i>Travel Behaviour & Society</i> , 2023, 30, 1-10.	2.4	5
384	Towards novel nano-based vaccine platforms for SARS-CoV-2 and its variants of concern: Advances, challenges and limitations. <i>Journal of Drug Delivery Science and Technology</i> , 2022, 76, 103762.	1.4	0
385	BBIBP-CorV Vaccination Reduces COVID-19 Severity Rate and Accelerates Anti-Viral Antibody Responses in Heterologous Omicron Infection. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
386	High-Speed Railways and the Spread of Covid-19. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
387	Global Biologic Characteristics of Variants of Concern and Variants of Interest of SARS-CoV-2. , 2022, , 161-181.		0
388	Recent update on treatment and preventive modalities for COVID-19 Omicron variant (B.1.1.529) in India: A comprehensive review. <i>Saudi Journal for Health Sciences</i> , 2022, 11, 83.	0.1	1
389	Assessing the Robustness of SARS-CoV-2 Vaccine Efficacy Trials: Systematic Review and Meta-Analysis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
390	SARS-CoV-2 Variants: Impact of Spike Mutations on Vaccine and Therapeutic Strategies. , 2022, , 143-160.		0
391	COVID-19 Vaccines Authorized by Stringent Regulatory Authorities and Vaccine Candidates Expecting Approval in 2021. , 2022, , 575-594.		0
392	Safety and Efficacy of the Two Doses Conjugated Protein-Based SOBERANA-02 COVID-19 Vaccine and of a Heterologous Three-Dose Combination with SOBERANA-PLUS: Double-Blind, Randomised, Placebo-Controlled Phase 3 Clinical Trial. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
393	SARS-CoV-2 Delta variant induces enhanced pathology and inflammatory responses in K18-hACE2 mice. <i>PLoS ONE</i> , 2022, 17, e0273430.	1.1	17
394	SARS-CoV-2 reinfections during the first three major COVID-19 waves in Bulgaria. <i>PLoS ONE</i> , 2022, 17, e0274509.	1.1	8
395	Genetic Load of SARS-CoV-2 in Aerosols Collected in Operating Theaters. <i>Applied and Environmental Microbiology</i> , 2022, 88, .	1.4	2
396	COVID-19 Vaccine Effectiveness Against Progression to In-Hospital Mortality in Zambia, 2021–2022. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	7

#	ARTICLE	IF	CITATIONS
397	SARS-CoV-2 Variants, Current Vaccines and Therapeutic Implications for COVID-19. <i>Vaccines</i> , 2022, 10, 1538.	2.1	12
398	An albumin-angiotensin converting enzyme 2-based SARS-CoV-2 decoy with FcRn-driven half-life extension. <i>Acta Biomaterialia</i> , 2022, , .	4.1	2
399	Characteristics of replication and pathogenicity of SARS-CoV-2 Alpha and Delta isolates. <i>Virologica Sinica</i> , 2022, 37, 804-812.	1.2	4
400	The Promise of Emergent Nanobiotechnologies for In Vivo Applications and Implications for Safety and Security. <i>Health Security</i> , 2022, 20, 408-423.	0.9	5
401	Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Vaccine Effectiveness. <i>Vaccines</i> , 2022, 10, 1751.	2.1	10
402	COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	77
403	The resurgence risk of COVID-19 in China in the presence of immunity waning and ADE: A mathematical modelling study. <i>Vaccine</i> , 2022, 40, 7141-7150.	1.7	13
404	SARS-CoV-2 variants of concern: a review. <i>Monaldi Archives for Chest Disease</i> , 0, , .	0.3	4
405	Coronavirus disease 2019 vaccine effectiveness among a population-based cohort of people living with HIV. <i>Aids</i> , 2022, 36, F17-F26.	1.0	13
406	Efficacy of COVID-19 Vaccination in People Living with HIV: A Public Health Fundamental Tool for the Protection of Patients and the Correct Management of Infection. <i>Infectious Disease Reports</i> , 2022, 14, 784-793.	1.5	5
407	Amphiphile-CpG vaccination induces potent lymph node activation and COVID-19 immunity in mice and non-human primates. <i>Npj Vaccines</i> , 2022, 7, .	2.9	4
408	Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial. <i>Clinical Infectious Diseases</i> , 2023, 76, 398-407.	2.9	24
410	HIV skews the SARS-CoV-2 B cell response towards an extrafollicular maturation pathway. <i>ELife</i> , 0, 11, .	2.8	6
411	Immunogenicity, efficacy, and safety of SARS-CoV-2 vaccine dose fractionation: a systematic review and meta-analysis. <i>BMC Medicine</i> , 2022, 20, .	2.3	3
414	Perspective Chapter: Emerging SARS-CoV-2 Variants of Concern (VOCs) and Their Impact on Transmission Rate, Disease Severity and Breakthrough Infections. <i>Infectious Diseases</i> , 0, , .	4.0	0
415	The health benefit of physical exercise on COVID-19 pandemic: Evidence from mainland China. <i>PLoS ONE</i> , 2022, 17, e0275425.	1.1	0
416	Bioinformatic Analysis of B- and T-cell Epitopes from SARS-CoV-2 Structural Proteins and their Potential Cross-reactivity with Emerging Variants and other Human Coronaviruses. <i>Archives of Medical Research</i> , 2022, 53, 694-710.	1.5	5
417	Novel coronavirus mutations: Vaccine development and challenges. <i>Microbial Pathogenesis</i> , 2022, 173, 105828.	1.3	7

#	ARTICLE	IF	CITATIONS
418	COVID-19 Vaccination in India. , 2022, , 255-278.		0
419	Success of nano-vaccines against COVID-19: a transformation in nanomedicine. Expert Review of Vaccines, 2022, 21, 1739-1761.	2.0	2
420	A review of COVID vaccines: success against a moving target. British Medical Bulletin, 2022, 144, 12-44.	2.7	5
421	Clinical and immune response characteristics among vaccinated persons infected with SARS-CoV-2 delta variant: a retrospective study. Journal of Zhejiang University: Science B, 2022, 23, 899-914.	1.3	2
422	Recent advances of nanotechnology in COVID 19: A critical review and future perspective. OpenNano, 2023, 9, 100118.	1.8	0
423	Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine (Covovax™) after homologous and heterologous two-dose regimens. International Journal of Infectious Diseases, 2023, 126, 64-72.	1.5	12
424	COVID-19 vaccines: Update of the vaccines in use and under development. Vacunas (English Edition), 2022, 23, S88-S102.	0.3	0
425	Formulation of SARS-CoV-2 Spike Protein with CpG Oligodeoxynucleotides and Squalene Nanoparticles Modulates Immunological Aspects Following Intranasal Delivery. Pharmaceutics, 2022, 14, 2539.	2.0	3
426	Efficacy and Safety of COVID-19 Vaccines—An Update. Diseases (Basel, Switzerland), 2022, 10, 112.	1.0	11
427	Nanomaterials to combat SARS-CoV-2: Strategies to prevent, diagnose and treat COVID-19. Frontiers in Bioengineering and Biotechnology, 0, 10, .	2.0	3
429	Post COVID-19 vaccination side effects and associated factors among vaccinated health care providers in Oromia region, Ethiopia in 2021. PLoS ONE, 2022, 17, e0278334.	1.1	2
430	Effectiveness of COVID-19 vaccines on hospitalization and death in Guilan, Iran: a test-negative case-control study. International Journal of Infectious Diseases, 2023, 128, 212-222.	1.5	9
431	Efficacy and safety of COVID-19 vaccines. The Cochrane Library, 2023, 2023, .	1.5	60
432	Mixed formulation of mRNA and protein-based COVID-19 vaccines triggered superior neutralizing antibody responses. MedComm, 2022, 3, .	3.1	1
433	A Retrospective Study of the Safety and Immunogenicity of MVC-COV1901 Vaccine for People Living with HIV. Vaccines, 2023, 11, 18.	2.1	3
434	Real-time online monitoring of insect cell proliferation and baculovirus infection using digital differential holographic microscopy and machine learning. Biotechnology Progress, 2023, 39, .	1.3	2
435	An Attention towards the Prophylactic and Therapeutic Options of Phytochemicals for SARS-CoV-2: A Molecular Insight. Molecules, 2023, 28, 795.	1.7	8
436	HIV and COVID-19 Disease. Seminars in Respiratory and Critical Care Medicine, 2023, 44, 035-049.	0.8	2

#	ARTICLE	IF	CITATIONS
437	Prevalent and immunodominant CD8 T cell epitopes are conserved in SARS-CoV-2 variants. <i>Cell Reports</i> , 2023, 42, 111995.	2.9	12
438	Effectiveness of the BBV-152 and AZD1222 vaccines among adult patients hospitalized in tertiary hospitals in Odisha with symptomatic respiratory diseases: A test-negative case-control study. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	0
439	Acute Adverse Events at a Mass Vaccination Site after the Third and Fourth COVID-19 Vaccinations in Japan. <i>Tohoku Journal of Experimental Medicine</i> , 2023, 259, 263-271.	0.5	3
440	Effects of tuberculosis and/or HIV-1 infection on COVID-19 presentation and immune response in Africa. <i>Nature Communications</i> , 2023, 14, .	5.8	17
441	Efficacy of Vaccine Protection Against COVID-19 Virus Infection in Patients with Chronic Liver Diseases. <i>Journal of Clinical and Translational Hepatology</i> , 2023, 000, 000-000.	0.7	0
442	Durability of Vaccine-Induced and Natural Immunity Against COVID-19: A Narrative Review. <i>Infectious Diseases and Therapy</i> , 2023, 12, 367-387.	1.8	22
443	COVID-19 Vaccines—All You Want to Know. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2023, 44, 143-172.	0.8	4
444	Developing a multiepitope vaccine for the prevention of SARS-CoV-2 and monkeypox virus co-infection: A reverse vaccinology analysis. <i>International Immunopharmacology</i> , 2023, 115, 109728.	1.7	14
445	Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial. <i>The Lancet Regional Health Americas</i> , 2023, 18, 100423.	1.5	16
446	Perspective Chapter: Cardiovascular Post-Acute COVID-19 Syndrome—Definition, Clinical Scenarios, Diagnosis, and Management. , 0, , .		1
447	T Cell Immune Responses against SARS-CoV-2 in the With Corona Era. <i>Biomedical Science Letters</i> , 2022, 28, 211-222.	0.0	0
449	Impact of Improper Storage of ChAdOx1-S (AstraZeneca) Vaccine on Its Efficacy and Safety. <i>Vaccines</i> , 2023, 11, 93.	2.1	0
450	Universal access to vaccines in post-COVID bioeconomy: Redesign for variants of concern and patent protection. , 2023, , 37-76.		0
451	Immunogenicity Characterization of COVID-19 Vaccines: A Systematic Review and Meta-analysis. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 0, 56, .	0.4	2
452	Upper respiratory tract mucosal immunity for SARS-CoV-2 vaccines. <i>Trends in Molecular Medicine</i> , 2023, 29, 255-267.	3.5	17
453	Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages. <i>Scientific Reports</i> , 2023, 13, .	1.6	26
454	A brief overview of various vaccines against nCOVID19, including safety, efficacy, reported cases, clinical trials, and progress. <i>Indian Journal of Health Sciences and Biomedical Research KLEU</i> , 2023, 16, 13.	0.1	1
455	Comparison of Preprint Postings of Randomized Clinical Trials on COVID-19 and Corresponding Published Journal Articles. <i>JAMA Network Open</i> , 2023, 6, e2253301.	2.8	0

#	ARTICLE	IF	CITATIONS
456	SARS-CoV-2 Variants Screening in Burkina Faso. <i>Journal of Medical Microbiology and Infectious Diseases</i> , 2022, 10, 135-140.	0.1	0
457	COVID-19 Vaccination in Korea. <i>Infection and Chemotherapy</i> , 2023, 55, 135.	1.0	9
458	Longitudinal IgA and IgG Response, and ACE2 Binding Blockade, to Full-Length SARS-CoV-2 Spike Protein Variants in a Population of Black PLWH Vaccinated with ChAdOx1 nCoV-19. <i>Viruses</i> , 2023, 15, 448.	1.5	0
459	An overview of the vaccine platforms to combat COVID-19 with a focus on the subunit vaccines. <i>Progress in Biophysics and Molecular Biology</i> , 2023, 178, 32-49.	1.4	16
460	Efficacy of SARS-CoV-2 vaccines and the dose-response relationship with three major antibodies: a systematic review and meta-analysis of randomised controlled trials. <i>Lancet Microbe</i> , The, 2023, 4, e236-e246.	3.4	46
462	Harnessing the Power of Venomous Animal-Derived Toxins against COVID-19. <i>Toxins</i> , 2023, 15, 159.	1.5	0
464	Introductory Chapter: Global Research Efforts toward the Development of COVID-19 Vaccines. , 0, , .		0
466	Update on the effectiveness of COVID-19 vaccines on different variants of SARS-CoV-2. <i>International Immunopharmacology</i> , 2023, 117, 109968.	1.7	17
467	Application of Traditional Vaccine Development Strategies to SARS-CoV-2. <i>MSystems</i> , 2023, 8, .	1.7	7
468	Retrospective, Observational Studies for Estimating Vaccine Effects on the Secondary Attack Rate of SARS-CoV-2. <i>American Journal of Epidemiology</i> , 0, , .	1.6	1
469	The impact of influenza vaccination on surgical outcomes in COVID-19 positive patients: An analysis of 43,580 patients. <i>PLoS ONE</i> , 2023, 18, e0281990.	1.1	0
470	The changing health impact of vaccines in the COVID-19 pandemic: A modeling study. <i>Cell Reports</i> , 2023, 42, 112308.	2.9	1
471	Heterologous prime-boost immunisation with mRNA- and AdC68-based 2019-nCoV variant vaccines induces broad-spectrum immune responses in mice. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
472	SARS-CoV-2 Vaccines, Vaccine Development Technologies, and Significant Efforts in Vaccine Development during the Pandemic: The Lessons Learned Might Help to Fight against the Next Pandemic. <i>Vaccines</i> , 2023, 11, 682.	2.1	7
473	Challenges and Recent Advancements in COVID-19 Vaccines. <i>Microorganisms</i> , 2023, 11, 787.	1.6	1
474	The immune evasion ability of Delta variant is comparable to that of Beta variant in South Africa. <i>BMC Public Health</i> , 2023, 23, .	1.2	2
475	Hybrid immunity provides protective advantage over vaccination or prior remote COVID-19 alone. <i>Open Forum Infectious Diseases</i> , 0, , .	0.4	2
476	Immunology of COVID-19. , 2024, , 52-71.		0

#	ARTICLE	IF	CITATIONS
477	SARS-CoV-2 RBD Conjugated to Polyglucin, Spermidine, and dsRNA Elicits a Strong Immune Response in Mice. <i>Vaccines</i> , 2023, 11, 808.	2.1	1
478	Vaccine Basics and the Development and Rollout of COVID-19 Vaccines. , 2024, , 326-348.		0
479	IgG1-Dominant Antibody Response Induced by Recombinant Trimeric SARS-CoV-2 Spike Protein with PIKA Adjuvant. <i>Vaccines</i> , 2023, 11, 827.	2.1	0
480	BBIBP-CorV vaccination accelerates anti-viral antibody responses in heterologous Omicron infection: A retrospective observation study in Shanghai. <i>Vaccine</i> , 2023, , .	1.7	2
481	Immune Imprinting and Implications for COVID-19. <i>Vaccines</i> , 2023, 11, 875.	2.1	10
500	Coronavirus Vaccines. , 2023, , 248-257.e4.		0
523	Nanoscale Vaccines for the Prevention of COVID-19. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2023, , 367-402.	0.2	0